花旗集团最新发布的研究报告显示,已将对远程医疗公司Hims & Hers Health Inc的股票评级从"卖出"上调至"中性"。与此同时,该机构将其目标股价从13.25美元显著调高至24美元,涨幅超过80%。
此次评级调整反映了花旗对该公司业务发展前景的重新评估。目标价的大幅提升可能基于对公司营收增长、市场份额扩大或盈利能力改善的积极预期。作为专注于男性与女性健康领域的远程医疗服务商,Hims & Hers Health Inc近期在扩大用户基础和优化服务模式方面取得进展,这或是引发机构重新评估其价值的关键因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.